Dr. Sylvia Wagner (female) is Head of the Department “Bioprocessing & Bioanalytics” at Fraunhofer IBMT. She studied chemistry at the University Karlsruhe. She gained her PhD thesis in the group of Prof. Dr. H. v. Briesen at IBMT. From 2008-2016 she was group manager at IBMT. Her main research topics are focused on nanobiotechnology and development of preclinical in vitro/ex vivo models in the field of nanotoxicology as well as nanomedicine. Nanoparticulate formulations for the specific drug targeting as well as for crossing of biological barriers were preclinically tested in different in vitro and ex vivo cell culture models. Her department has established e.g., several blood-brain barrier cell culture models, a gastrointestinal barrier model, a lung model and a dermal barrier model for permeation studies. Her department was and still is involved in several joint research projects in the field of drug delivery systems based on nanotechnologies which were and are funded by EU and BMBF (“NanoDrug”; “NanoCancer”; “NanoBrain”; “BioTrap for CCC”) as well as projects supported by the German Federal Armed Forces and the private industry. One of her actual projects called “GITCare” is focused on the oral delivery of nanoparticulate packaged drugs for tumour therapy. Furthermore, several projects based on nanoparticle risk assessment are coming more and more into focus, e.g., the BMBF funded projects “MINAC” and “NanoUmwelt” and the EU funded project “HISENTS”.
- Position: Micro- Nano- Biotechnologies
- Affiliation: Fraunhofer IBMT
- Email: email@example.com